Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, March 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0796197/Portal-Hypertension-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Portal Hypertension Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Portal Hypertension Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Portal Hypertension Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Portal Hypertension Therapeutics market
Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Portal Hypertension Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Portal Hypertension Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Portal Hypertension Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 52 Portal Hypertension Cirrhosis Therapeutics - Introduction 62.1 Overview 62.2 Portal Venous System 62.3 Pathophysiology 72.4 Epidemiology 82.5 Causes 82.6 Child-Pugh Classification of Cirrhosis 102.7 Symptoms 112.8 Diagnosis 112.9 Treatment 122.9.1 Variceal hemorrhage 122.9.2 Ascites 142.10 GlobalData Pipeline Report Guidance 153 Portal Hypertension Therapeutics - Market Characterization 163.1 Portal Hypertension Therapeutics Market Size (2006-2011) - Global 163.2 Portal Hypertension Therapeutics Market Forecast (2011-2019) - Global 173.3 Portal Hypertension Therapeutics Market Size (2006-2011) - The US 183.4 Portal Hypertension Therapeutics Market Forecast (2011-2019) - The US 193.5 Portal Hypertension Therapeutics Market Size (2006-2011) - France 203.6 Portal Hypertension Therapeutics Market Forecast (2011-2019) - France 213.7 Portal Hypertension Therapeutics Market Size (2006-2011) - Germany 223.8 Portal Hypertension Therapeutics Market Forecast (2011-2019) -Germany 233.9 Portal Hypertension Therapeutics Market Size (2006-2011) - Italy 243.10 Portal Hypertension Therapeutics Market Forecast (2011-2019) - Italy 253.11 Portal Hypertension Therapeutics Market Size (2006-2011) - Spain 263.12 Portal Hypertension Therapeutics Market Forecast (2011-2019) - Spain 273.13 Portal Hypertension Therapeutics Market Size (2006-2011) - The UK 283.14 Portal Hypertension Therapeutics Market Forecast (2011-2019) - The UK 293.15 Portal Hypertension Therapeutics Market Size (2006-2011) - Japan 303.16 Portal Hypertension Therapeutics Market Forecast (2011-2019) - Japan 313.17 Drivers and Barriers 323.17.1 Drivers for the Portal Hypertension Therapeutics Market 323.17.2 Barriers for the Portal Hypertension Therapeutics Market 323.18 Opportunity and Unmet Need Analysis 333.19 Key Takeaway 344 Portal Hypertension Therapeutics - Competitive Assessment 354.1 Overview 354.1.1 Strategic Competitor Assessment 354.2 Product Profile for the Major Marketed Products in the Portal Hypertension Therapeutics Market 364.2.1 Beta-Blockers 364.2.2 Vasopressin and its Analogs 364.2.3 Somatostatin and its Analogs 364.3 Key Takeaway 365 Portal Hypertension Therapeutics - Pipeline Assessment 375.1 Overview 375.2 Strategic Pipeline Assessment 375.3 Portal Hypertension Therapeutics Pipeline - Pipeline by Clinical Phase of Development 375.4 Pipeline Analysis by Phase of Development 385.4.1 Portal Hypertension Therapeutics - Phase II/III Pipeline 385.4.2 Portal Hypertension Therapeutics - Phase II Pipeline 385.5 Technology Trends Analytical Framework 385.6 Pipeline by Mechanism of Action 395.7 Profiles of Key Late Stage Pipeline Drugs 405.7.1 Octreolin (octreotide) 405.7.2 Sapropterin (tetrahydrobiopterin) 405.7.3 Udenafil (DA-8519) 405.8 Key Takeaway 416 Portal Hypertension Therapeutics - Clinical Trials Mapping 426.1 Clinical Trials by Region/Country (US, EU5 and Japan) 426.2 Clinical Trials by Phase 436.3 Clinical Trials by Trial Status 446.4 Overall Sponsors 456.5 Prominent Sponsors 466.6 Companies Participating in Therapeutics Clinical Trials 477 Portal Hypertension Therapeutics - Strategic Assessment 487.1 Portal Hypertension Therapeutics - Implications for Future Market Competition 488 Portal Hypertension Therapeutics - Future Players 498.1 Introduction 498.2 Company Profile 498.2.1 Chiasma (Israel) Ltd. 498.2.2 Dong-A Pharmaceutical Co Ltd (Dong-A) 509 Portal Hypertension Therapeutics - Deals 5110 Portal Hypertension Therapeutics - Appendix 5210.1 Market Definitions 5210.2 Abbreviation 5210.3 Methodology 5310.3.1 Coverage 5310.3.2 Secondary Research 5310.3.3 Forecasting 5410.3.4 Primary Research 5610.3.5 Expert Panel Validation 5610.4 Contact Us 5610.5 Disclaimer 5610.6 Sources 57
List of Tables
Table 1: Child-Pugh Classification of Cirrhosis 10Table 2: Status Classification of Cirrhosis 11Table 3: Portal Hypertension Therapeutics Market, Global, Revenue ($bn), 2006-2011 16Table 4: Portal Hypertension Therapeutics Market, Global, Forecast ($bn), 2011-2019 17Table 5: Portal Hypertension Therapeutics Market, the US, Revenue ($m), 2006-2011 18Table 6: Portal Hypertension Therapeutics Market, the US, Forecast ($m), 2011-2019 19Table 7: Portal Hypertension Therapeutics Market, France, Revenue ($m), 2006-2011 20Table 8: Portal Hypertension Therapeutics Market, France, Forecast ($m), 2011-2019 21Table 9: Portal Hypertension Therapeutics Market, Germany, Revenue ($m), 2006-2011 22Table 10: Portal Hypertension Therapeutics Market, Germany, Forecast ($m), 2011-2019 23Table 11: Portal Hypertension Therapeutics Market, Italy, Revenue ($m), 2006-2011 24Table 12: Portal Hypertension Therapeutics Market, Italy, Forecast ($m), 2011-2019 25Table 13: Portal Hypertension Therapeutics Market, Spain, Revenue ($m), 2006-2011 26Table 14: Portal Hypertension Therapeutics Market, Spain, Forecast ($m), 2011-2019 27Table 15: Portal Hypertension Therapeutics Market, the UK, Revenue ($m), 2006-2011 28Table 16: Portal Hypertension Therapeutics Market, the UK, Forecast ($m), 2011-2019 29Table 17: Portal Hypertension Therapeutics Market, Japan, Revenue ($m), 2006-2011 30Table 18: Portal Hypertension Therapeutics Market, Japan, Forecast ($m), 2011-2019 31Table 19: Portal Hypertension Therapeutics - Phase II/III Pipeline, 2011 38Table 20: Portal Hypertension Therapeutics - Phase II Pipeline, 2011 38Table 21: Portal Hypertension Therapeutics - Clinical Trials by Country, 2011 42Table 22: Portal Hypertension Therapeutics - Clinical Trials by Phase, 2011 43Table 23: Portal Hypertension Therapeutics - Clinical Trials by Status, 2011 44Table 24: Portal Hypertension Therapeutics - Overall Sponsors, 2011 45Table 25: Portal Hypertension Therapeutics - Prominent Sponsors, 2011 46Table 26: Portal Hypertension Therapeutics - Company Participating in Therapeutics Clinical Trials, 2011 47Table 27: Portal Hypertension Therapeutics - Pipeline by Company, 2011 49Table 28: Chiasma (Israel) - Portal Hypertension Therapeutics Pipeline 49Table 29: Dong-A Pharmaceutical Co., Ltd. - Portal Hypertension Therapeutics Pipeline 50Table 30: Portal Hypertension Therapeutics, Global, Deals, 2011 51
List of Figures
Figure 1: Portal Venous System 6Figure 2: Portal Hypertension: Pathophysiology 8Figure 3: Portal Hypertension: Prehepatic Causes 9Figure 4: Portal Hypertension: Hepatic Causes 9Figure 5: Portal Hypertension: Posthepatic Causes 10Figure 6: Transjugular Intrahepatic Portosystemic Shunt (TIPS) 13Figure 7: Portal Hypertension Therapeutics Market, Global, Revenue ($bn), 2006-2011 16Figure 8: Portal Hypertension Therapeutics Market, Global, Forecast ($bn), 2011-2019 17Figure 9: Portal Hypertension Therapeutics Market, the US, Revenue ($m), 2006-2011 18Figure 10: Portal Hypertension Therapeutics Market, the US, Forecast ($m), 2011-2019 19Figure 11: Portal Hypertension Therapeutics Market, France, Revenue ($m), 2006-2011 20Figure 12: Portal Hypertension Therapeutics Market, France, Forecast ($m), 2011-2019 21Figure 13: Portal Hypertension Therapeutics Market, Germany, Revenue ($m), 2006-2011 22Figure 14: Portal Hypertension Therapeutics Market, Germany, Forecast ($m), 2011-2019 23Figure 15: Portal Hypertension Therapeutics Market, Italy, Revenue ($m), 2006-2011 24Figure 16: Portal Hypertension Therapeutics Market, Italy, Forecast ($m), 2011-2019 25Figure 17: Portal Hypertension Therapeutics Market, Spain, Revenue ($m), 2006-2011 26Figure 18: Portal Hypertension Therapeutics Market, Spain, Forecast ($m), 2011-2019 27Figure 19: Portal Hypertension Therapeutics Market, the UK, Revenue ($m), 2006-2011 28Figure 20: Portal Hypertension Therapeutics Market, the UK, Forecast ($m), 2011-2019 29Figure 21: Portal Hypertension Therapeutics Market, Japan, Revenue ($m), 2006-2011 30Figure 22: Portal Hypertension Therapeutics Market, Japan, Forecast ($m), 2011-2019 31Figure 23: Portal Hypertension Therapeutics, Drivers and Restraints, 2011 33Figure 24: Opportunity and Unmet Need in the Portal Hypertension Therapeutics Market, 2011 34Figure 25: Portal Hypertension Therapeutics - Strategic Competitor Assessment, 2011 35Figure 26: Portal Hypertension Therapeutics - Pipeline by Phase of Clinical Development, 2011 37Figure 27: Portal Hypertension Therapeutics - Technology Trends Analytics Framework, 2011 38Figure 28: Portal Hypertension Therapeutics - Technology Trends Analytics Framework - Description, 2011 39Figure 29: Portal Hypertension Therapeutics - Mechanism of Action, 2011 39Figure 30: Portal Hypertension Therapeutics - Clinical Trials by Country, 2011 42Figure 31: Portal Hypertension Therapeutics - Clinical Trials by Phase, 2011 43Figure 32: Portal Hypertension Therapeutics - Clinical Trials by Status, 2011 44Figure 33: Portal Hypertension Therapeutics - Overall Sponsors, 2011 45Figure 34: Portal Hypertension Therapeutics - Prominent Sponsors, 2011 46Figure 35: Portal Hypertension Therapeutics - Company Participating in Therapeutics Clinical Trials, 2011 47Figure 36: Portal Hypertension Therapeutics - Implications for Future Market Competition, 2011 48Figure 37: GlobalData Market Forecasting Model 55
Companies mentioned
Chiasma (Israel) Ltd.
Dong-A Pharmaceutical Co Ltd (Dong-A)
To order this report:Therapy Industry: Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article